What is Zacks Research’s Estimate for CRDF FY2026 Earnings?

Cardiff Oncology, Inc. (NASDAQ:CRDF) – Equities researchers at Zacks Research raised their FY2026 earnings estimates for Cardiff Oncology in a research note issued on Tuesday, May 26th. Zacks Research analyst J. Vandermosten now expects that the company will post earnings per share of ($0.74) for the year, up from their prior forecast of ($0.81). The consensus estimate for Cardiff Oncology’s current full-year earnings is ($0.67) per share. Zacks Research also issued estimates for Cardiff Oncology’s FY2027 earnings at ($0.76) EPS and FY2028 earnings at ($0.74) EPS.

A number of other brokerages have also commented on CRDF. Wall Street Zen lowered shares of Cardiff Oncology from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Piper Sandler dropped their price objective on shares of Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Cardiff Oncology in a report on Monday, May 18th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Cardiff Oncology in a research note on Wednesday, January 28th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $10.10.

Cardiff Oncology Stock Down 6.7%

Shares of NASDAQ:CRDF opened at $1.81 on Thursday. Cardiff Oncology has a 12 month low of $1.48 and a 12 month high of $4.56. The company’s fifty day simple moving average is $1.69 and its 200 day simple moving average is $2.05. The firm has a market cap of $123.75 million, a price-to-earnings ratio of -2.70 and a beta of 1.36.

Cardiff Oncology (NASDAQ:CRDF) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). Cardiff Oncology had a negative return on equity of 95.51% and a negative net margin of 8,527.43%.The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.09 million.

Institutional Investors Weigh In On Cardiff Oncology

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Laurion Capital Management LP grew its position in shares of Cardiff Oncology by 7.3% in the 4th quarter. Laurion Capital Management LP now owns 2,646,738 shares of the company’s stock valued at $7,437,000 after acquiring an additional 180,866 shares during the period. Acorn Capital Advisors LLC boosted its holdings in shares of Cardiff Oncology by 39.3% during the 3rd quarter. Acorn Capital Advisors LLC now owns 1,962,084 shares of the company’s stock worth $4,042,000 after buying an additional 553,317 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Cardiff Oncology by 7.5% during the 2nd quarter. Geode Capital Management LLC now owns 1,498,838 shares of the company’s stock worth $4,723,000 after buying an additional 104,409 shares during the period. Franklin Resources Inc. bought a new stake in Cardiff Oncology in the 4th quarter valued at about $3,388,000. Finally, State Street Corp boosted its holdings in Cardiff Oncology by 4.0% in the 4th quarter. State Street Corp now owns 1,191,647 shares of the company’s stock valued at $3,349,000 after purchasing an additional 45,288 shares during the period. 16.29% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Cardiff Oncology

Here are the key news stories impacting Cardiff Oncology this week:

• Neutral Sentiment: Zacks Research reiterated that Cardiff Oncology is expected to remain unprofitable, with FY2026 EPS at $(0.74), FY2027 at $(0.76), and FY2028 at $(0.74), while the current full-year consensus is $(0.67).
• Neutral Sentiment: Zacks also projected quarterly losses for Q2 2026, Q3 2026, and Q4 2026 in the range of $(0.18) to $(0.20) per share, suggesting no near-term profitability inflection.
• Neutral Sentiment: Noble Financial similarly forecast ongoing quarterly losses and said FY2026 EPS should be $(0.78), reinforcing the view that Cardiff Oncology remains a pre-profit biotech with limited earnings visibility.
• Negative Sentiment: Noble Financial cut its Q2 2026 and Q3 2026 EPS estimates, indicating analysts are becoming more conservative about Cardiff Oncology’s near-term financial outlook.
• Negative Sentiment: Zacks lowered its FY2027 EPS estimate to $(0.76) from $(0.75), a small but negative revision that may weigh on sentiment.
• Negative Sentiment: Recent earnings estimates remain below zero across the board, which can pressure CRDF shares as investors wait for clearer clinical or commercial catalysts.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.